



## Determination of Escitalopram in Human Plasma by High Performance Liquid Chromatography-Tandem Mass Spectrometry

Carlos E.M. de SOUSA <sup>1\*</sup>, Felipe N. BONIFÁCIO <sup>2</sup>, Danilo C.G. BEDOR <sup>1</sup>,  
Thayse M.SILVA <sup>1</sup>, Virna .L.S. RAMOS <sup>1</sup>, José H. de SOUZA FILHO <sup>1</sup>,  
Leila B. LEAL <sup>1</sup>, Amanda T.C. OLIVEIRA <sup>1</sup> & Davi P. de SANTANA <sup>1\*</sup>.

<sup>1</sup> Núcleo de Desenvolvimento Farmacêutico e Cosmético, Rua Professor Arthur de Sá s/n,  
Cidade Universitária, CEP 50740-520, Recife, Pernambuco, Brasil.

<sup>2</sup> Laboratório de Pesquisa Translacional Prof. C. Anthony Hart,  
Instituto de Medicina Integral Prof. Fernando Figueira –IMIP–  
Rua dos Coelhos, 300 Boa Vista, CEP 50070-550, Recife, Pernambuco, Brasil.

**SUMMARY.** A rapid (3.0 min) and sensitive (LLOQ 0.5 ng/mL) analytical method for the quantitation of Escitalopram (ETP) in human plasma is described. The method is based on High-Performance Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) using paroxetine as internal standard (I.S.). Sample preparation involved precipitation extraction with acetonitrile. The chromatographic separation was achieved on a ACE C18 (125 x 4,6 mm) reversed-phase column and a mobile phase containing acetonitrile/water (60:50 v/v, add 0.2 % formic acid), in isocratic conditions. The target analytes were transferred into a triple quadrupole mass spectrometer equipped with an electrospray ionization source for mass detection. The ion transitions selected for MRM detection were:  $m/z$  325.2 > 109.2 and 330.0 > 192.0 for ETP and I.S., respectively. The assay was linear in the concentration range of 0.5-50 ng/mL. The mean recovery for ETP was 97.69 %. Intra- and inter-day precision (R.S.D.) were < 10.5 % and < 8.2 %, respectively and the accuracy (R.E.) was in the range  $\pm$  12.23 %. The method was successfully applied to a single oral dose pharmacokinetics study in 28 healthy Brazilian human volunteers.

**KEY WORDS:** Brazilian volunteers, Escitalopram, LC-MS/MS, Pharmacokinetics, Validation.

\* Authors to whom correspondence should be addressed. *E-mail:* eduardo.miranda@nudfac.com.br or d-santana@bol.com.br